Legend Biotech requests that their press release NewsItemId: 20211206005107 “Legend Biotech Announces Submission of New Drug Application to Japanese Regulatory Authority for BCMA CAR-T Therapy Cilta-cel for the Treatment of Relapsed or Refractory Multiple Myeloma by Janssen” be killed.
--(BUSINESS WIRE)-- Legend Biotech requests that their press release NewsItemId: 20211206005107 “Legend Biotech Announces Submission of New Drug Application to Japanese Regulatory Authority for BCMA CAR-T Therapy Cilta-cel for the Treatment of Relapsed or Refractory Multiple Myeloma by Janssen” be killed.
The release was issued prematurely by Legend Biotech. The release will be reissued at a later date.
Contacts
Investor Contacts:
Joanne Choi, Senior Manager of Investor Relations and Corporate Communications, Legend Biotech joanne.choi@legendbiotech.com or investor@legendbiotech.com
Crystal Chen, Manager of Investor Relations and Corporate Communications, Legend Biotech crystal.chen@legendbiotech.com
Press Contact:
Tina Carter, Corporate Communications Lead, Legend Biotech
tina.carter@legendbiotech.com
(908) 331-5025
Source:
View this news release online at:
http://www.businesswire.com/news/home/20211206005107/en
